How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?
Objective: To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer. Results: Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with...
| Publicado en: | Abdominal Radiology Vol. 45; no. 12; pp. 4031 - 4040 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Dec2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Objective: To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer. Results: Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with suspicion of prostate cancer who are considering first-time or repeat biopsy, blood- and urine-based assays can improve the prediction of harboring clinically significant disease and may reduce unnecessary biopsy. Blood- and urine-based biomarkers have been evaluated in association with prostate MRI, offering insights that might augment decision-making in the pre and post-MRI setting. Tissue-based genomic and proteomic assays have also been developed that provide independent assessments of prostate cancer aggressiveness that can complement imaging. Conclusion: A growing number of non-imaging biomarkers are available to assist in clinical decision-making for men with known or suspected prostate cancer. An appreciation for the intersection of imaging and biomarkers may improve clinical care and resource utilization for men with prostate cancer. |
|---|